Australian Clinical Labs (ACL) H2 2025 earnings summary

Executive summary

• Achieved 6.4% revenue growth year-over-year to $741.3m for FY25, with underlying EBIT up 8.7% to $68.0m, despite challenging market conditions and outperforming market growth in MBS outlays.

• Delivered against revenue and EBIT guidance, with margin expansion and robust free cash flow supporting significant capital returns to shareholders.

• Maintained a sustainable competitive advantage as the only national pathology provider with a single national laboratory information system, driving cost efficiencies and customer service enhancements.

• Returned $44.0m to shareholders via dividends and share buyback, while reducing net debt by $8.4m.

• Continued investment in business and technology integration, including digital and operational initiatives.

Financial highlights

• Revenue reached $741.3m, up 6.4% year-over-year; underlying EBIT was $68.0m, up 8.7%; underlying EBIT margin improved to 9.2%.

• Underlying NPAT rose 7.7% to $34.0m; underlying EPS up 13.4% to 17.8cps.

• Free cash flow before interest, tax, and financing increased 30.2% to $70.8m.

• Final fully franked dividend of 9.0cps declared, with a total FY dividend of 12.5cps (72% payout ratio).

• Net debt/EBITDA reduced to 0.3x, with net debt reduced by $8.4m and $13.0m of debt repaid in FY25.

Outlook and guidance

• FY26 revenue guidance: $760m–$780m; underlying EBIT: $67m–$73m.

• Guidance reflects ongoing market softness, government fee cuts, and continued investment in revenue initiatives and operational efficiencies.

• Lower end of guidance considers potential for slower market growth; H1/H2 seasonality expected to mirror FY25.

• Initiatives in development expected to generate at least $8m EBIT in FY27, mainly from digital billing, automation, and price increases.